中国P站

Microbiome; Viral Infections; Gut Microbiota; Immune Response; Antiviral Immunity; Gut-Lung Axis; SARS-CoV-2; COVID-19; Pathogenesis; Therapeutic Targets

Introduction

The host microbiome, particularly the gut microbiota, exerts a profound influence on the susceptibility, progression, and ultimate outcome of a wide array of viral infections. This critical impact is observed through various mechanisms, including direct interactions with viruses, the modulation of host antiviral immunity, and the direct effect on viral replication. This demonstrates the microbiome's pivotal role in shaping the host's overall response to viral pathogens and their associated diseases [1].

Commensal microbiota are recognized as central players in the intricate relationship with the host immune system during the course of viral infections. These microbial communities are instrumental in priming both innate and adaptive immune responses, thereby significantly influencing crucial aspects such as viral clearance, the severity of the disease, and even the efficacy of vaccines. This clearly positions the microbiota as a key modulator of the host's antiviral immunity [2].

Extending this understanding, a comprehensive review details the significant impact of the host microbiota on various viral infections and the subsequent antiviral immune responses. It elaborates on how the specific microbial composition can effectively modulate both innate and adaptive immunity, directly affecting viral replication, the pathways of pathogenesis, and ultimately, the efficacy of antiviral therapies [7].

The microbiome is unequivocally positioned as a crucial regulator of both viral infection and overall immunity. Microbial communities are known to influence pivotal stages of viral activity, including viral entry into host cells, their replication cycles, and their persistence within the host. Beyond these direct viral interactions, the microbiome also plays a significant role in shaping both local and systemic immune responses. This multifaceted influence strongly emphasizes the substantial therapeutic potential that lies in strategically targeting the microbiome for interventions [8].

Furthermore, dedicated studies have intensely focused on the immunomodulatory roles that the microbiota plays in viral pathogenesis. Researchers explore how these microbial communities can either directly or indirectly influence host susceptibility to viral infections, dictate the progression of the disease, and impact the overall efficacy of antiviral immune responses, thereby facilitating the identification of promising therapeutic targets for future interventions [9].

Investigating the dynamic interplay between the gut microbiome and various viral infections reveals a complex and essential relationship. It highlights how commensal bacteria and their diverse metabolites actively influence viral replication, profoundly shape host immune responses, and ultimately determine disease outcomes. This compelling evidence underscores the significant potential of microbiota modulation as a viable and effective strategy for both preventing and treating a range of viral diseases [10].

A critical area of emerging understanding revolves around the gut microbiome’s specific role in respiratory viral infections, particularly through the concept of the gut-lung axis. In this intricate axis, metabolites and distinct immune signals that originate from the gut exert influence over immune responses in the lungs. This significantly impacts an individual's susceptibility to, and the severity of, common respiratory infections such as influenza and Respiratory Syncytial Virus (RSV) [3].

This perspective is further reinforced by work that emphasizes the critical nature of host-microbiota interactions in respiratory viral infection, again focusing intensely on the gut-lung axis. It graphically illustrates how disruptions within the gut microbiota can directly lead to heightened susceptibility and an exacerbated pathology in respiratory infections, simultaneously highlighting potential avenues for therapeutic intervention [5].

The complex interplay among viruses, the microbiome, and immunity is especially pertinent when considering the gut-lung axis in the context of COVID-19. Here, microbial dysbiosis has been clearly shown to exacerbate inflammatory responses and severely compromise antiviral defense mechanisms, thereby significantly impacting the progression and overall severity of the disease [6].

The intricate and specific relationship between SARS-CoV-2 and the gut microbiome has also garnered substantial scientific attention. Research elucidates how dysbiosis within the gut can profoundly impact COVID-19 pathogenesis, influencing critical aspects such as viral replication, strategies of immune evasion employed by the virus, and the ultimate severity of the disease. Importantly, this domain also extends to considering novel therapeutic interventions specifically aimed at targeting the gut microbiota as a means to manage or treat COVID-19 [4].

Description

The host microbiome stands as a fundamental determinant of an individual's vulnerability, the course, and the outcome of various viral infections. Its influence spans direct interactions with viral particles, sophisticated modulation of the host's antiviral immunity, and direct effects on viral replication processes. This dynamic system underscores the microbiome's essential role in shaping the host’s adaptive and innate responses to viral pathogens, thereby influencing disease progression [1]. The microbiome acts as a critical and pervasive regulator of viral infection and immunity, with microbial communities dictating crucial aspects like viral entry into host cells, their subsequent replication, and their long-term persistence within the host. Beyond these direct influences, the microbiome also profoundly shapes both local immune responses at infection sites and systemic immunity throughout the body [8]. This complex interplay extends to the gut microbiome and diverse viral infections, where commensal bacteria and their metabolic byproducts are critical in influencing viral replication rates, orchestrating host immune responses, and ultimately defining disease outcomes. These observations highlight the significant potential of modulating the microbiota as a strategic intervention for preventing or treating viral diseases [10].

Commensal microbiota play an intricate and indispensable role in shaping the host immune system's response to viral challenges. These microbial communities are crucial for priming both innate and adaptive immune responses, which in turn dictate viral clearance efficiency, the overall severity of the disease experienced, and even the effectiveness of vaccines [2]. This significant impact of host microbiota on viral infections and the subsequent antiviral immune responses is further elaborated by detailed reviews. They highlight how specific microbial compositions can intricately modulate both innate and adaptive immunity, which consequently affects viral replication kinetics, the underlying pathogenesis of the infection, and the overall efficacy of antiviral therapies being employed [7]. Moreover, extensive research has specifically focused on the immunomodulatory roles of the microbiota in viral pathogenesis. These studies investigate how microbial communities can either directly interact with immune cells or indirectly influence them through metabolites, thereby affecting host susceptibility, disease progression, and the vigor of antiviral immune responses. Such investigations are pivotal for identifying novel therapeutic targets to intervene in viral diseases [9].

A particularly salient area of discovery concerns the emerging understanding of the gut microbiome's integral role in respiratory viral infections, primarily facilitated by the gut-lung axis. This axis represents a bidirectional communication pathway where metabolites and various immune signals generated within the gut exert considerable influence over immune responses occurring in the lungs. This intricate communication impacts an individual's susceptibility to, and the ultimate severity of, common respiratory infections such as influenza and Respiratory Syncytial Virus (RSV) [3]. This perspective is underscored by further work emphasizing the critical nature of host-microbiota interactions in respiratory viral infections, with a distinct focus on the gut-lung axis. This research vividly illustrates how perturbations or disruptions in the gut microbiota can directly lead to heightened susceptibility and an exacerbated pathological presentation in respiratory infections. Crucially, it also points towards innovative potential therapeutic avenues that leverage this axis to improve respiratory health [5].

The complex interplay between SARS-CoV-2 and the gut microbiome has become a significant focal point in recent years. This area of study reveals how dysbiosis, an imbalance in the gut microbial community, can profoundly impact COVID-19 pathogenesis. Such imbalances can influence critical aspects including viral replication rates, the strategies of immune evasion employed by SARS-CoV-2, and the overall severity of the resulting disease. Importantly, research in this domain also explores and considers therapeutic interventions specifically targeting the gut microbiota as a means to mitigate the effects of COVID-19 [4]. This exploration is further supported by investigations into the interplay between viruses, the microbiome, and immunity, with a specific lens on the gut-lung axis in the context of COVID-19. It meticulously highlights how microbial dysbiosis can significantly exacerbate inflammatory responses throughout the body and crucially compromise the host's antiviral defense mechanisms, thereby adversely impacting disease progression and severity in COVID-19 patients [6].

Collectively, these findings demonstrate that the microbiome is not merely an inert bystander but an active, crucial player in the host's battle against viral infections. The consistent identification of its roles in modulating immunity, influencing viral life cycles, and contributing to disease pathogenesis across various viral types, including respiratory pathogens and SARS-CoV-2, opens significant new frontiers. The emphasis on therapeutic potential, through targeting the microbiome for immunomodulation and disease prevention or treatment, provides compelling directions for future research and clinical application. Understanding and manipulating these microbial communities offers a promising avenue for developing novel strategies to bolster host defense against viral threats [8, 9, 10].

Conclusion

The host microbiome significantly influences the susceptibility, progression, and outcome of diverse viral infections. This impact stems from direct interactions with viruses, modulation of host antiviral immunity, and alterations in viral replication. Commensal microbiota play a critical role as modulators of antiviral immunity, effectively priming both innate and adaptive immune responses. This modulation influences viral clearance, disease severity, and the overall efficacy of vaccines. A prominent area of research highlights the gut-lung axis, a pathway where metabolites and immune signals originating from the gut profoundly affect immune responses within the lungs. This axis is particularly relevant in shaping susceptibility and severity for respiratory viral infections, including common pathogens like influenza and RSV, and crucially, SARS-CoV-2. Dysbiosis, or disruptions in the gut microbiota, has been shown to increase susceptibility to respiratory infections and exacerbate pathological conditions. Such imbalances can intensify inflammatory responses and compromise the host's antiviral defenses, significantly impacting the progression and severity of diseases such as COVID-19. The microbiome is recognized as a crucial regulator of viral infection and immunity, with microbial communities influencing viral entry, replication, and persistence. They also shape both local and systemic immune responses. This emerging understanding of host-microbiota interactions points towards considerable therapeutic potential in targeting the microbiome. The dynamic interplay between the gut microbiome and viral infections, wherein commensal bacteria and their metabolites influence viral replication, host immune responses, and disease outcomes, positions microbiota modulation as a strategic approach for preventing or treating various viral diseases. Investigating the immunomodulatory roles of the microbiota in viral pathogenesis continues to reveal promising therapeutic targets.

References

1. Wenbo L, Qibin L, Yuanyuan Z (2021) .Trends Microbiol 29:512-525.

   , ,

2. Yongqiang D, Chunxiao Y, Zhifei L (2022) .Front Immunol 13:947475.

   , ,

3. Anupam S, Jessica MHT, Rachel SJ (2022) .Front Cell Infect Microbiol 12:887038.

   , ,

4. Ziliang L, Ruiyang W, Xiaolong W (2023) .Gut Microbes 14:2210878.

   , ,

5. Jinhu Z, Hongmei F, Mengyan Z (2023) .Cell Biosci 13:17.

   , ,

6. Xiaoting D, Xin L, Yue W (2023) .Int J Mol Sci 24:3519.

   , ,

7. Jinhu Z, Jun L, Hongmei F (2022) .Front Microbiol 13:1032822.

   , ,

8. Ryan DS, Sawsan G, Rebecca KS (2023) .Trends Microbiol 31:589-601.

   , ,

9. Jia-Xuan F, Peng-Peng H, Xin-Yue S (2023) .Viruses 15:520.

   , ,

10. Jiawen W, Wei Z, Xin M (2024) .Cell Biosci 14:62.

    , ,